Thursday 03 September 2020
Books – Sayed Metwally
Almost 3 months ago, the Minister of Health and Population, Hala Zayed, announced the success of the trial of injecting people with the new Corona virus with plasma recovering from the virus in order to treat critical cases.
The minister explained, according to what was published by the Cabinet Presidency page on “Facebook”, that this experiment was carried out within the framework of Egypt’s efforts to find treatment lines, and the countries of the world are racing to find treatment for patients infected with the virus.
The minister indicated that a trial of recovering plasma injection was applied to some critically ill Coronavirus patients in hospitals of the Ministry of Health and Population, and the plasma was also provided to two university hospitals after its request, as the experiment showed promising initial results through a good recovery rate for patients and reducing the patients’ need for devices Ventilation with an increase in recovery rates and patients discharged from hospitals.
Although the US Food and Drug Administration announced the possibility of using the plasma of patients recovering from the emerging corona virus in the treatment of critical cases, given that it contains antibodies to the virus, which gives the possibility for improvement in these cases, especially with research evidence in many countries of the world, but it seems that scientists They exploded a new surprise, which is presented by “Masrawy”, according to the British newspaper “Daily Mail”.
American health officials are divided over plasma treatment for Covid-19, as an advisory committee from the National Institutes of Health in America said that there is not enough evidence that plasma therapy is effective in treating patients.
On August 23, the experimental treatment was granted emergency use permission by the US Food and Drug Administration, and NIH experts say analysis of a study showed no difference in overall seven-day survival and recovery between patients who received antibody-rich plasma and those. Those who have received plasma with low levels of antibodies, and they cannot recommend or discourage its use to treat Covid-19.
The NIH group said in a statement: ‘There are currently no data from well-controlled, sufficiently powered randomized clinical trials that demonstrate the efficacy and safety of plasma in treating corona, and there is insufficient data to recommend either with or against the use of plasma in treating COVID-19. 19 “.
To approve the treatment, the scientists noted the Mayo Clinic study, in which there was a 35 percent reduction in the death rate among patients under the age of 80 who received the plasma.
Of the 35,000 coronavirus patients, the team said deaths were lower among people who were given plasma within three days of diagnosis, and also among those who received plasma with the highest levels of antibodies compared to less-rich plasma, but it was not a formal study because the patients were treated differently. In hospitals across the country.
This means that the Mayo Clinic cannot prove that the plasma – along with the other care they received – was the real reason for the improvement. Moreover, experts say that “reducing the mortality rate by 35 percent” is an exaggerated number.
The results show that 8.7 percent of patients treated with plasma within three days of diagnosis died after seven days, compared to 11.9 percent of those treated four days or more. This is a difference of 3.2 percent, not 35 percent.
Plasma therapy is an experimental treatment in which the plasma taken from a patient with Covid-19 virus in a critical condition is used, and the hope is that the antibodies and immunity from the blood of a healthy person will be transferred to the patient, and from this, the infected person will develop the necessary antibodies to fight the coronavirus .
The treatment was first used during the 1918 Spanish flu pandemic, a situation not far from the Coronavirus pandemic, people can donate plasma more than once, but they have to wait several weeks after donating.
In April, the US Food and Drug Administration authorized the use of plasma to treat Covid-19 patients, but said it should be on a case-by-case basis, as patients who receive it may have conditions such as respiratory failure or the failure of many organs.